In hepatocellular carcinoma patients, TP53 mutation is associated with decreased levels of glutaminase 2: functionally, glutaminase 2 suppression is linked to enhanced anchorage-independent survival and increased tumorigenesis in hepatocellular carcinoma [42]. Here, TP53 is linked to hepatocellular carcinoma.